Abbvie makes a big bet on preclinical integrin inhibitors

Snippets

Abbvie is a little late to the integrin inhibitor party. But the $100m in up-front cash it dropped on a research deal with Morphic Therapeutic yesterday suggests the company believes it can take the fight to its more advanced rivals. Morphic’s candidates, which are still preclinical, are administered orally, giving them an edge over most other projects in development – although Eisai’s AJM300 and Protagonist’s PTG-100, both being tested in ulcerative colitis, are also oral. Targeting integrins is thought to halt fibrosis, which is implicated in many disorders, as shown by the wide range of diseases in which this class is being evaluated. Privately held Morphic is being tight-lipped about exactly what indications it is looking at, saying only that it is focused on autoimmune and fibrotic diseases and cancer. The most advanced of the company’s five projects is an alpha v beta 6 inhibitor – upregulation of this integrin has been linked with cancer. Fibrosis is also involved in the much-hyped liver disease Nash; Morphic might be eyeing this space itself, as the smaller company has retained cost-sharing rights in liver fibrosis indications.

Integrin inhibitors in clinical development
Product Company Indication Pharma class Administration
Marketed
Entyvio Takeda Ulcerative colitis, Crohn's Anti-alpha 4 beta 7 integrin MAb Intravenous
Phase III
Etrolizumab Roche Ulcerative colitis, Crohn's Anti-beta 7 integrin MAb Subcutaneous
SHP647 Shire Ulcerative colitis, Crohn's Anti-integrin MAb Subcutaneous
AJM300 Eisai/Ajinomoto/Kissei Pharmaceutical Ulcerative colitis  Alpha 4 integrin inhibitor Oral
Phase II
PTG-100 Protagonist Therapeutics Ulcerative colitis, IBD Alpha 4 beta 7 integrin inhibitor Oral
CB-06-02 Cassiopea Genital warts Integrin inhibitor Topical
BG00011 Biogen Idiopathic pulmonary fibrosis Anti-alpha 5 beta 6 integrin MAb Subcutaneous
ASP5094 Astellas Pharma Rheumatoid arthritis Anti-alpha 9 integrin MAb Intravenous
Abituzumab Merck KGaA/SFJ Pharmaceuticals Colorectal cancer Anti-integrin alpha 5 MAb Intravenous
SF0166 Scifluor Life Sciences AMD, diabetic macular oedema Integrin alpha 5 beta 3 inhibitor Eye drop
Luminate Allegro Ophthalmics AMD, diabetic macular oedema Integrin inhibitor Intravitreal injection
Phase I
GSK3008348 Glaxosmithkline Idiopathic pulmonary fibrosis Alpha 5 beta 6 integrin inhibitor Nebulised
Source: EvaluatePharma.

Share This Article